Immunotherapy with chemo and targeted drug for colon cancer in the belly
Part of Cancer clinical trials.
This Phase 2 trial tests serplulimab (immunotherapy) combined with FOLFIRI chemo plus bevacizumab for colon cancer that has spread to the lining of the abdomen (peritoneal metastases). It aims to shrink these tumors and improve outcomes when surgery can’t fully remove them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon cancer in biopsy tissue, and it matches pMMR/MSS and RAS/BRAF “wild-type” test results
- Your scans show colon cancer has spread to the belly lining (peritoneal metastases)
- Doctors found tumor tissue during surgery that could not be fully removed (not CC0/1)
- You’re age 18–75, and you can do day-to-day activities fairly well (ECOG 0–2), with an expected survival of more than 12 weeks
- Your blood counts, kidney function, and liver tests are in acceptable ranges for treatment
- You can safely handle immunotherapy, chemotherapy, and surgery, and you can sign the study consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests if adding immunotherapy and an anti-angiogenesis drug to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. You may benefit if your tumor is in the lower part of the rectum and you haven't had prior cancer treatment.
This trial tests a combination of three drugs (FOLFOX chemotherapy, fruquintinib, and serplulimab) as a first treatment for people with a specific type of colorectal cancer that cannot be surgically removed. The goal is to shrink the cancer enough to make surgery possible.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
Hear when a new Unresectable Colon Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.